Indeed, two preclinical studies, in murine models, in breast and prostate cancers respectively have highlighted that inhibition of Orai3 impairs tumor growth and metastasis [36, 37] suggesting Orai3 as a useful therapeutic target in oncology. Here, ORAI3 is linked to prostate cancer.